Wolfgang Dummer M.D., Ph.D.
Net Worth
Last updated:
What is Wolfgang Dummer M.D., Ph.D. net worth?
The estimated net worth of Dr. Wolfgang Dummer M.D., Ph.D. is at least $4,028,765 as of 2 Feb 2023. He owns shares worth $2,791,099 as insider, has earned $8,946 from insider trading and has received compensation worth at least $1,228,720 in Rigel Pharmaceuticals, Inc..
What is the salary of Wolfgang Dummer M.D., Ph.D.?
Dr. Wolfgang Dummer M.D., Ph.D. salary is $614,360 per year as Executive Vice President & Chief Medical Officer in Rigel Pharmaceuticals, Inc..
How old is Wolfgang Dummer M.D., Ph.D.?
Dr. Wolfgang Dummer M.D., Ph.D. is 59 years old, born in 1966.
What stocks does Wolfgang Dummer M.D., Ph.D. currently own?
As insider, Dr. Wolfgang Dummer M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | Executive Vice President & Chief Medical Officer | 72,459 | $38.52 | $2,791,099 |
What does Rigel Pharmaceuticals, Inc. do?
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Wolfgang Dummer M.D., Ph.D. insider trading
Rigel Pharmaceuticals, Inc.
Dr. Wolfgang Dummer M.D., Ph.D. has made only one insider trade in 2023, according to the Form 4 filled with the SEC. He sold 5,389 units of RIGL stock worth $8,946 on 2 Feb 2023.
As of 2 Feb 2023 he still owns at least 72,459 units of RIGL stock.
Rigel Pharmaceuticals key executives
Rigel Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Wolfgang Dummer M.D., Ph.D. (59) Executive Vice President & Chief Medical Officer
- Mr. David A. Santos (62) Executive Vice President & Chief Commercial Officer
- Mr. Dean L. Schorno CPA (62) Executive Vice President & Chief Financial Officer
- Mr. Raul R. Rodriguez (64) Pres, Chief Executive Officer & Director
- Ms. Dolly A. Vance (60) Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec.